Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Gynecologic Oncology|December 14, 2012
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)F Cognetti, A Bagnato, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2008
P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevanceA Torsello, C Garufi, M Cosimelli, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 19, 2007
Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancerE Bria, P Visca, F Novelli, et al.
Tumori|December 23, 1998
Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trialF Boccardo, A Rubagotti, L Canobbio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinomaG Cocconi, P Carlini, A Gamboni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancerS Di Cosimo, A Alimonti, G Ferretti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2006
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive diseaseP Papaldo, A Fabi, G Ferretti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2005
More information, more choice: an Italian database for oncology patientsA Bogliolo, W Russell-Edu, G Alloro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancerS Gori, F Montemurro, S Spazzapan, et al.
Pageof 12